Prostate Cancer

TALAPRO-2 is the first phase 3 study to evaluate talazoparib plus enzalutamide as a first-line treatment in patients with metastatic castration resistant prostate cancer.

Real-world data hint that darolutamide may lengthen time to treatment discontinuation and more, in patients with non-metastatic castration-resistant prostate cancer.

According to Joshua M. Lang, MD, MS, the importance of molecular understanding, especially in initially focusing on the genetics of PCa and how that can inform new therapies, has been one of the revolutions in PCa.

During a Targeted Oncology™ Case-Based Roundtable™ event, Alicia K. Morgans, MD, MPH, discussed results of the phase 3 PROpel trial of patients with metastatic castration-resistant prostate cancer. This is the second of 2 articles based on this event.

Findings from the phase 3 PROpel have led to the FDA approval of olaparib in combination with abiraterone and prednisone or prednisolone for a prostate cancer subgroup.

The FDA has approved the flotufolastat F 18 injection for positron emission tomography of prostate-specific membrane antigen–positive lesions in patients with prostate cancer.

Tanya Dorff, MD, discusses the main findings from a phase 1 study of patients with metastatic castration-resistant prostate cancer.

In an interview with Targeted Oncology, Pedro Barata, MD, MSc, discussed the current therapies available, unmet needs, and ongoing studies for patients with metastatic prostate cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Alicia K. Morgans, MD, MPH, and participants discussed situations when they would use a PARP inhibitor to treat patients with metastatic castration-resistant prostate cancer in the second or third line. This is the first of 2 articles based on this event.

Arash Rezazadeh Kalebasty, MD, discusses the dose modification impact of the addition of darolutamide for patients with metastatic hormone sensitive prostate cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Tanya B. Dorff, and participants, discussed the case of a patient with metastatic castration-resistant prostate cancer who has already received enzalutamide and docetaxel.

In an interview with Targeted Oncology™, Andrew J. Armstrong, MD gave a first-hand perspective on the discussion held during the recent ODAC meeting and explained what the discussion and vote mean for the future of olaparib plus abiraterone in metastatic castration-resistant prostate cancer.

Significant differences in the incidence of genitourinary events, depression, and ischemic and thrombotic events were observed based on race among patients with prostate cancer after receiving androgen deprivation therapy.

It was announced that the phase 3 EMBARK study met its primary end point in patients with nonmetastatic castration-sensitive prostate cancer with high-risk biochemical recurrence.

The Oncologic Drugs Advisory Committee has discussed the approval application for olaparib plus abiraterone and prednisone or prednisolone for patients with metastatic castration-resistant prostate cancer and voted on its potential future.

In an interview with Targeted Oncology, John Nakayama, MD discussed 2 recently reported, practice-changing studies in endometrial cancer, and where the field is heading.

The FDA continues to push forward PSMA-targeted therapies to address unmet needs for patients with metastatic castration-resistant prostate cancer.

A phase 1 trial of EPI-7386 will evaluate the safety, pharmacokinetics, drug-drug interactions, and preliminary anti-tumor activity of the agent in combination with apalutamide or abiraterone acetate plus prednisone.

John T. Nauseef, MD, PhD, discusses an investigational prostate-specific membrane antigen targeted therapy for the treatment of metastatic castration-resistant prostate cancer.

Chad Tang, MD, discusses currently available treatment options and recent research in the prostate cancer space.

In an interview with Targeted Oncology, Jones T. Nauseef, MD, PhD, discussed the investigational PSMA targeted therapy, 225Ac-J591, and results from a phase 1 study.

During a Targeted Oncology™ Case-Based Roundtable™ event, Yousef Zakharia, MD, discussed next-line therapy for a patient with metastatic castration-resistant prostate cancer who has received docetaxel and an androgen receptor–targeted therapy.

A new apalutamide tablet has become available for oncologists in the United States who treat non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer.

In an interview with Targeted Oncology, Neal D. Shore, MD, FACS, gave an overview of previous and updated findings from the ARAMIS trial for patients with nonmetastatic castration-resistant prostate cancer.

In separate, live virtual events, Neeraj Agarwal, MD, and Alicia Morgans, MD, MPH, discussed options for a patient with metastatic castration-resistant prostate cancer after multiple lines of therapy.